Cell and gene therapy

EU flag
#Advanced Therapy Medicinal Products (ATMPs) #Alliance for Regenerative Medicine #Cell and gene therapy #EFPIA #EU #European Commission #European Federation of Pharmaceutical Industries and Associations #Market reporting

Can Europe become a major player in cell and gene therapy?

With European life sciences R&D investment at a 20-year low, biopharmaceutical associations and MEPs are calling on the EU to modernise its policies. DDW’s Diana Spencer asks what will be needed for Europe to compete in the growing global market for advanced therapies.  A new report by Charles River Associates… Read More

#Exclusive Content #Market Reports

#Cell and gene therapy #FDA #Gene therapy #Haemophilia #Regulatory

FDA approves first gene therapy for haemophilia B

The US Food and Drug Administration (FDA) has approved Hemgenix (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy for appropriate adults with haemophilia B.   The drug is approved for the treatment of adults with haemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening… Read More

#News #Regulatory

Cell and gene therapies
#Cell and gene therapy #mRNA #pDNA #Webinar

Early phase support for plasmid DNA supply to secure future manufacturing

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell or gene therapies that require pDNA as a starting material. Building a robust supply of GMP-grade pDNA requires that quality be a… Read More

Webinar date:
Brought to you by Catalent
#Webinars

T cells attacking cancer
#Cancer #Cancer immunotherapy #Cell and gene therapy #Cell therapy #HER2 #Immunotherapy #Oncology #Precision medicine #T-Cells #Tumours

Positive interim data for cell therapy in solid tumours

Triumvira Immunologics has revealed positive clinical data from its ongoing TACTIC‑2 Phase I/II trial of TAC01-HER2 in patients with human epidermal growth factor receptor 2 (HER2) positive solid tumours.  These interim data demonstrate that TAC01-HER2 is well-tolerated and clinical activity was observed in the two higher dosing cohorts,… Read More

#Cancer Research #News

#Biologics #Cell and gene therapy #Clinical research #Comment #FDA #Regulatory

The significance of FDA industry guidance on cell and gene therapies 

On 4 November 2022, the FDA’s Center for Biologics Evaluation and Research released guidance for the industry on studying multiple versions of a cellular or gene therapy (CGT) product in an early-phase clinical trial in a single disease1. This guidance finalises the draft guidance of the same title dated September… Read More

#Exclusive Content #Opinion #Regulatory

Cell and gene therapy
#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Webinar: How to resolve barriers to CGT discovery

Stream this free webinar, hosted by DDW and supported by Catalent, Early phase support for plasmid DNA supply helps secure future manufacturing for advanced therapies. The webinar was presented by Matthias Craig, Senior Manager Product Development, Catalent. One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production… Read More

#News

Doctor and patient
#Cell and gene therapy #Investment #Point of care services #United States

CGT company secures investment for point of care services

Orgenesis has agreed up to $50 million investment from Metalmark Capital in its US-based point of care services subsidiary, Morgenesis.  The investment will consist of an upfront investment of $30 million and two future investments of $10 million each, subject to the achievement of certain milestones.  Morgenesis will use the… Read More

#Business & Investment #News

Builders checking plans
#Biologics / Biotechnology #Biotech hubs #Cell and gene therapy #Drug discovery #Expansion #Investment #Laboratory #Manufacturing

Space to innovate: where are biotech’s top expansions?

Expansions to laboratory space throughout the drug discovery industry can only be a good thing – new centres of innovation will bring more space to grow, more advanced technologies, improved sustainability and new employment opportunities.  While there have been a significant number of new facilities built in the US,… Read More

#Editor's Choice #News

Cell and gene therapy
#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Webinar: Overcome barriers to CGT innovation

Watch this free webinar, hosted by DDW and supported by Catalent, which will be presented by Matthias Craig, Senior Manager Product Development, Catalent. One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based… Read More

#News

#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Exclusive webinar: How to remove the barriers to CGT innovation

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene therapies that require pDNA as a starting material.  Watch this free webinar – Early phase support for plasmid DNA supply… Read More

#News

Cell and gene therapy
#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Secure future manufacturing for advanced therapies

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene therapies that require pDNA as a starting material.  Watch this free webinar – Early phase support for plasmid DNA supply… Read More

#News

#Advanced Therapies Europe #CAR-T #Cell and gene therapy #Cell therapy #Collaboration

On the European CGT landscape, zebras and the future of medicine

Listen to this article on the DDW podcast: Alongside industry professionals interested in the cell and gene therapy landscape in Europe, DDW’s Multimedia Editor Megan Thomas was welcomed to Advanced Therapies Europe 2022 by Phacilitate’s Vice President, Becky Johnson-Kent. Johnson-Kent introduced the notion of the zebra company and compared its two-fold… Read More

#Editor's Choice #Exclusive Content

Cell and gene therapy
#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Webinar: Optimise plasmid production process and supply

This on-demand webinar, hosted by DDW and supported by Catalent, is presented by Matthias Craig, Senior Manager Product Development, Catalent. One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene… Read More

#News

Blood samples in lab
#Blood donation #Cell and gene therapy #Scotland

New blood donor centre opens in Glasgow

A new blood donor centre in Glasgow, Scotland has been opened to support cell and gene therapy research.  BioIVT’s new facility is located in the West of Scotland Science Park, which is home to more than 40 life science and technology businesses.   The donor center… Read More

#News

#Bioproduction #Cell and gene therapy #mRNA #mRNA-based vaccines #pDNA #Plasmid DNA #Webinar

Webinar addresses CGT challenges and how to resolve them

One critical bottleneck in Cell and Gene Therapy (CGT) manufacturing is the production of high-quality plasmid DNA (pDNA), a vital building block for mRNA-based vaccines, viral vector-based cell, or gene therapies that require pDNA as a starting material.  Watch this on-demand webinar – Early phase support for plasmid DNA supply… Read More

#News